Considering combination versus sequential chemotherapy in metastatic breast cancer

Aug 05, 2009

Both combination and sequential single-agent chemotherapy are reasonable options to treat metastatic breast cancer, but the choice between the two should ultimately be based on patient- and disease-related factors, according to a new commentary published online August 5 in the Journal of the National Cancer Institute.

Whether to use several simultaneously or single agents sequentially, one after the other, is a controversial issue. To explore this question, the European School of Oncology Metastatic Breast Cancer Task Force held an open debate on the relative benefits of combination versus sequential therapy at the 6th European Breast Cancer Conference.

In this commentary, Fatima Cardoso, M.D., of the Jules Bordet Institute in Brussels, and colleagues summarize the recommendations of that task force, which includes the use of sequential chemotherapy with a single agent for patients with advanced metastatic breast cancer without rapid progression or life-threatening metastasis, and for those who do not need rapid symptom or disease control.

The authors do not take one side over the other. Instead, they discuss the contributions and caveats of existing data on the two therapies. They do, however, note that because metastatic breast cancer is incurable, quality of life and overall survival should be the endpoints against which any systemic therapy is evaluated.

"Ultimately, the choice between combination and sequential systemic therapy for metastatic must involve an open discussion of potential side effects and logistical requirements with patients, taking into consideration the cost and availability of chemotherapeutic agents in local clinical practice settings," the authors write.

Source: (news : web)

Explore further: All-clear for nonlinear optical imaging

add to favorites email to friend print save as pdf

Related Stories

Drug combination shrinks breast cancer metastases in brain

Dec 16, 2007

A combination of a "targeted" therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer, according to data presented by Dana-Farber ...

Docetaxel given after doxorubicin reduces recurrence

Jan 08, 2008

Adding the drug docetaxel to anthracycline-based chemotherapy slightly improved disease-free survival in breast cancer patients, according to a randomized clinical trial published online January 8 in the Journal of the Na ...

Recommended for you

All-clear for nonlinear optical imaging

34 minutes ago

High power femto-second laser pulses used for in vivo nonlinear optical imaging can form DNA products, which may lead to carcinogenesis. A modified cancer risk model now shows that the cancer risk is negligible ...

Pain and itch may be signs of skin cancer

16 hours ago

Asking patients if a suspicious skin lesion is painful or itchy may help doctors decide whether the spot is likely to be cancerous, according to a new study headed by Gil Yosipovitch, MD, Chairman of the Department of Dermatology ...

Genetics of cancer: Non-coding DNA can finally be decoded

20 hours ago

Cancer is a disease of the genome resulting from a combination of genetic modifications (or mutations). We inherit from our parents strong or weak predispositions to developing certain kinds of cancer; in addition, we also ...

User comments : 0